Sponsors (47)
Subjects MFP-selected Part B drugs to standard ASP+6 payment, requires quarterly manufacturer rebates and reporting, and sets coinsurance at MFP+6 with a rebate-linked cap.
The bill aims to lower some Medicare Part B patient costs and shore up the Part B trust fund by redirecting manufacturer rebates and standardizing payment rules, but it risks raising manufacturer incentives to increase list prices, leaving some beneficiaries with large coinsurance exposure, and imposing new compliance costs.
Medicare beneficiaries: coinsurance for selected Part B drugs will be tied to MFP+6, which can lower out-of-pocket costs for many patients who use those drugs.
Taxpayers and Medicare beneficiaries: additional manufacturer rebate revenue is redirected into the Medicare Part B trust fund, which could reduce federal program net costs and help support Part B solvency.
Hospitals, health systems and CMS: removing a payment carve‑out aligns and simplifies Part B payment methodology, increasing consistency across drugs and reducing special-case complexity for administrators and providers.
Patients with chronic conditions and Medicare beneficiaries: requiring substantial quarterly manufacturer rebates could incentivize higher list prices, reduce product availability, or delay product introductions, which may raise costs or limit access.
Medicare beneficiaries: some individuals will still face coinsurance equal to 20% of MFP+6, which for very costly therapies can remain high and leave significant out-of-pocket exposure.
Manufacturers, hospitals and CMS: increased reporting and enforcement requirements raise compliance costs that may be passed through to payors or consumers or increase administrative burdens for providers and agencies.
Based on analysis of 2 sections of legislative text.
Official title: To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.
Introduced July 7, 2025 by Gregory Francis Murphy · Last progress July 7, 2025
Amends Medicare Part B payment law to remove a special payment exception for certain drugs and biologics designated under the Maximum Fair Price (MFP) program, subjects those products to the standard ASP+6 payment methodology, and creates a new quarterly manufacturer rebate and reporting framework tied to MFP. It also sets beneficiary coinsurance for those medicines based on the negotiated MFP price plus 6% with an inflation-rebate-related cap and establishes timing and remittance rules for manufacturer rebates. The bill requires the Secretary of HHS to report quarterly units furnished and per-unit rebate amounts to manufacturers, who must remit rebates within 30 days; it preserves other statutory rebates and ties the new Part B payment and beneficiary cost-sharing to MFP outcomes. The amendment renumbers existing statutory text to insert the new rebate provisions into the Part B payment statute.